Study links J&J epilepsy med to birth defects

Just a week after FDA experts narrowly rejected a new black-box warning on epilepsy drugs, new research shows that one of them, Johnson & Johnson's Topamax, may increase the risk of birth defects. In a small study--203 patients--scientists found a 14-fold increase in the risk of birth defects. The risk appeared to be higher among patients who took Topamax in combination with valproate (Depakote) or other epilepsy meds.

Experts stressed that the results need to be confirmed, because the study was small. And pregnant women with epilepsy should not stop taking the drug, they said, because seizures can cause even greater damage to a fetus. Women using it to prevent migraines should stop if they're pregnant or trying to get pregnant, they said. They didn't mention off-label use of Topamax--sometimes in combination with valproate--for bipolar disorder, but presumably those patients ought to discuss with their doctors, too.

- read the Los Angeles Times story
- see the article in the Washington Post

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.